Predictors of time to remission in children with steroid-sensitive nephrotic syndrome: a prospective observational study in Nepal Authors: Ranjita Baral, Mukesh Bhatta, Seraj Ahmed Khan, Punita Yadav, Shankar Prasad Yadav Published: 2025 ABSTRACT BackgroundNephrotic syndrome is the most prevalent glomerular disease in children and corticosteroids are the mainstay of treatment. Although most children are steroid-sensitive, the response time varies. There is very limited research determining the factors that influence time to remission following steroid therapy. This study aims to identify predictors of time to remission in children with steroid-sensitive nephrotic syndrome (SSNS) at a tertiary level hospital in Nepal.MethodsA prospective observational study was conducted from June 2022 to May 2023 following ethical approval. Fifty-four children with SSNS aged 1–14 years were enrolled and prospectively followed with daily urine albumin dipstick test at home after initiating standard-dose steroid therapy until remission was achieved. The time to remission was recorded. Patients were categorized into early and late responder groups using a 9-day cut-off post-hoc. Independent student’s t-test, Mann-Whitney U test, fisher exact test and chi-square test were used to compare clinical and laboratory variables between groups.ResultsAmong 54 participants enrolled, 44 (81.5%) presented with a first episode and 10 (18.5%) with a relapse. The cohort had a male-to-female ratio of 2:1. The median age at onset was 5.0 years (IQR: 4.0, 9.0). The mean time to remission was 8.6 ± 1.7 days. Thirty-two (59.2%) participants were classified as early responders (< 9 days) and 22 (40.8%) as late responders (≥ 9 days). Remission was delayed in patients with hypertension and hematuria, although this trend was not statistically significant.ConclusionNone of the clinical variables (like age, gender, religion, geographical region, socioeconomic status, episode type (first episode/relapse), patient related factors like anemia, AKI, hypertension, ) and laboratory variables (like microscopic hematuria, raised serum creatinine, degree of hypoalbuminemia, hypercholesterolemia and severity of proteinuria) were significantly associated with time to remission in our analysis. This highlights the complexity of predicting steroid response and emphasizes the need for larger, multi-center studies to identify robust predictors of remission dynamics in pediatric nephrotic syndrome. Background Nephrotic syndrome is the most common acquired childhood kidney disease, with an estimated global incidence of 2 to 3 per 100,000 children per year [1]. It is characterized by a triad of nephrotic-range proteinuria (> 1 g/m²/day or ≥ 40 mg/m²/hr., a urine protein: creatinine ratio > 2 mg/mg, or ≥ 3 + protein on urine dipstick), hypoalbuminemia (albumin < 3 g/dL), and edema [2]. Corticosteroids are the cornerstone of treatment and most of the children exhibit steroid sensitivity with variable response rate. The mechanisms of action of steroid in nephrotic syndrome are complex and multifaceted as corticosteroids may act through both genomic and non-genomic pathways. Recent studies have highlighted steroid role in restoring glomerular permeability and podocyte integrity, thereby explaining variable patient’s response [3, 4]. Role of other factors, such as age of onset, gender, anemia, hypertension, kidney function and lipid abnormalities may influence the time to remission after initiation of steroid therapy [5]. Although several regional studies have been conducted which focused mostly on predictors of relapse, very few have prospectively determined factors influencing time to remission. This study is focused on time to remission rather than relapse frequency. This study conducted in Nepalese children with SSNS treated under standard ISPN guidelines evaluated the demographic, clinical, and laboratory variables as potential predictors of time to remission after starting standard dose steroid therapy. This study may add insight in treatment response patterns and risk stratification in South Asian Pediatric Population. Therefore, steroid treatment duration in steroid sensitive nephrotic syndrome may be shortened. Methods Study design and setting A single-center, prospective observational study was conducted at the Department of Pediatrics and Adolescent Medicine at B.P Koirala Institute of Health Sciences, Dharan, Nepal. The study ran from June 2022 to May 2023. Ethics approval and consent to participate The study protocol was approved by the Institutional Review Committee (IRC) of B.P. Koirala Institute of Health Sciences (Reference number:457/079/080-IRC). Written informed consent was obtained from the parents or legal guardians of all participants prior to enrolment. This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. Study participants Children aged 1–14 years presenting with a first episode of nephrotic syndrome or a relapse (including frequent relapses, infrequent relapses, and steroid-dependent cases) were eligible for inclusion. Participants were recruited consecutively from both outpatient department (OPD) and inpatients. The exclusion criteria were: secondary nephrotic syndrome due to SLE, diabetes mellitus, infections such as Hepatitis C or HIV, nephritic-nephrotic syndrome, already on treatment with calcineurin inhibitors, a positive tuberculosis screening test, or refusal of parental consent. Study definitions Remission: Defined as trace or negative protein on urine dipstick testing for three consecutive days.Early Responders: Participants who achieved remission in < 9 days from the initiation of steroid therapy.Late Responders: Participants who achieved remission in ≥ 9 days.Hypertension: Defined as blood pressure ≥ 95th percentile for age, sex, and height.Acute Kidney Injury (AKI): Defined according to the KDIGO criteria (2012) as:An increase in serum creatinine ≥ 0.3 mg/dl within 48 h or.An increase in serum creatinine ≥ 1.5 times from baseline within prior 7 days.Urine output < 0.5 ml/kg/hour for 6 h [6]. Remission: Defined as trace or negative protein on urine dipstick testing for three consecutive days. Remission: Defined as trace or negative protein on urine dipstick testing for three consecutive days. Early Responders: Participants who achieved remission in < 9 days from the initiation of steroid therapy. Early Responders: Participants who achieved remission in < 9 days from the initiation of steroid therapy. Late Responders: Participants who achieved remission in ≥ 9 days. Late Responders: Participants who achieved remission in ≥ 9 days. Hypertension: Defined as blood pressure ≥ 95th percentile for age, sex, and height. Hypertension: Defined as blood pressure ≥ 95th percentile for age, sex, and height. Acute Kidney Injury (AKI): Defined according to the KDIGO criteria (2012) as:An increase in serum creatinine ≥ 0.3 mg/dl within 48 h or.An increase in serum creatinine ≥ 1.5 times from baseline within prior 7 days.Urine output < 0.5 ml/kg/hour for 6 h [6]. Acute Kidney Injury (AKI): Defined according to the KDIGO criteria (2012) as: An increase in serum creatinine ≥ 0.3 mg/dl within 48 h or.An increase in serum creatinine ≥ 1.5 times from baseline within prior 7 days.Urine output < 0.5 ml/kg/hour for 6 h [6]. An increase in serum creatinine ≥ 0.3 mg/dl within 48 h or. An increase in serum creatinine ≥ 0.3 mg/dl within 48 h or. An increase in serum creatinine ≥ 1.5 times from baseline within prior 7 days. An increase in serum creatinine ≥ 1.5 times from baseline within prior 7 days. Urine output < 0.5 ml/kg/hour for 6 h [6]. Urine output < 0.5 ml/kg/hour for 6 h [6]. Those children presenting with features fulfilling these criteria were classified as having AKI. Steroid resistant nephrotic syndrome (SRNS)-Defined as failure to achieve remission after 4 weeks of treatment with standard dose daily prednisolone therapy. Socioeconomic status: -According to modified Kuppuswamy scale modified for Nepal, it is categorized into Upper class, upper middle class, lower middle class, upper lower class and lower class [7]. Steroid resistant nephrotic syndrome (SRNS)-Defined as failure to achieve remission after 4 weeks of treatment with standard dose daily prednisolone therapy. Steroid resistant nephrotic syndrome (SRNS)-Defined as failure to achieve remission after 4 weeks of treatment with standard dose daily prednisolone therapy. Socioeconomic status: -According to modified Kuppuswamy scale modified for Nepal, it is categorized into Upper class, upper middle class, lower middle class, upper lower class and lower class [7]. Socioeconomic status: -According to modified Kuppuswamy scale modified for Nepal, it is categorized into Upper class, upper middle class, lower middle class, upper lower class and lower class [7]. Sample size calculation The sample size was calculated based on a previous study by Rai et al. [5], using the comparison of two means. A sample size of 54 was determined to provide adequate statistical power. The cut-off to define early versus late responders was exploratory, based on median time to remission observed in our cohort and determined post-hoc to ensure comparable group sizes for analysis. Data collection and procedures Blood Pressure was measured using manual sphygmomanometer with an appropriate cuff size. Three readings taken at 5 min interval was averaged and taken for analysis. After diagnostic confirmation, all participants received standard-dose oral prednisolone at 60 mg/m²/day (maximum 60 mg/day), administered in 1–2 divided doses, according to the Indian Society of Pediatric Nephrology (ISPN) guidelines [2]. Patients presenting with relapse were screened for underlying infections, which were treated appropriately before steroid initiation. A standardized data collection form was used to record detailed demographic data (age, gender, socioeconomic status and geographical area), clinical history, and examination findings. Baseline investigations included a complete blood count, serum creatinine, serum electrolytes, a full lipid profile, urinalysis and spot urine protein to creatinine ratio. Parents were instructed on how to perform and record daily urine dipstick tests at home in a provided logbook. Participants were followed up regularly every alternate day via telephone and weekly in the OPD till they achieved remission. Outcome measures Time to remission following initiation of standard dose steroid therapy was recorded as the primary outcome. Occurrence of complications like hypertension, AKI, hyponatremia, hematuria and association of demographic and laboratory variables with time to remission were recorded as secondary outcome. Statistical analysis Data were entered into Microsoft Excel 2019 and analyzed using SPSS for Windows, version 23.0. The normality of continuous variables was tested using Shapiro-Wilk test. Normally distributed data were presented as mean ± standard deviation (SD) and skewed data as median with interquartile range (IQR). Categorical variables were presented as frequencies and percentages. The independent student’s t-test (for normally distributed data) and the Mann-Whitney U test (for skewed data) were used to compare continuous variables between early and late responder groups. The Chi-square test or Fisher’s exact test was used for categorical variables. Univariate logistic regression was performed to assess the association of each clinical and laboratory variables with time to remission (early vs. late responders). Clinically relevant variables and those with p < 0.2 in univariate analysis were included in a multivariate logistic regression model to identify independent predictors. Results were presented as odds ratios (OR) with 95% confidence intervals (CI) and p-values. A two-sided p-value of < 0.05 was considered statistically significant. Results Baseline characteristics A total of 54 children were enrolled. Of these, 36 (66.7%) were male and 18 (33.3%) were female, giving a male-to-female ratio of 2:1. A first episode of nephrotic syndrome was the presentation for 44 (81.5%) participants, while 10 (18.5%) presented with a relapse. The median age of onset was 5.0 years (IQR: 4.0, 6.0). The baseline demographic, clinical, and laboratory characteristics of the cohort are summarized in Table 1. Table 1Baseline characteristics of the study cohort (N = 54)VariableValuesN (%) Demographic characteristics Median age of onset(years)5.0 (4.0, 9.0) Gender MaleFemale36 (66.7)18 (33.3) Status of nephrotic syndrome First episodeRelapse(FRNS, IFRNS, SDNS)44 (81.5)10 (18.5) Geographical Distribution Hilly regionTerai region7(13)47(87) Socio-economic status Upper middle classLower middle classUpper lower class17(31.5)29(53.7)8(14.8) Clinical Features at Presentation Edema FacialPedalGeneralized10(18.5)17(31.5)27(50)Anemia9 (16.7)Hematuria (Microscopic)3 (5.6)Hypertension5 (9.3)Acute Kidney Injury (AKI)4 (7.4)Hyponatremia18 (33.3)Hypokalemia2 (3.7) Laboratory Parameters Hemoglobin(g/dl) *12.3(1.4).Urea(mg/dl) *24.0 (17.7, 34.0)Creatinine(mg/dl) *0.4 (0.3, 0.5)Sodium(mEq/L) *136.5(133.7,138.2)Potassium(mEq/L) *4.3(3.9,4.7)Total protein(g/dl) *4.4 (0.4)Serum Albumin(g/dl) *1.8(0.4)Total Cholesterol(mg/dl) *430.5(125.8)Serum LDL (mg/dl) *295.4(95)Serum HDL (mg/dl) *71.9 (24.8)Serum VLDL (mg/dl) *49.5 (36.8, 62.6)Serum Triglycerides(mg/dl) *250.5(188.5,341)24 h urinary protein(mg/m2/hr) *74(51.5,87)Spot urine protein: creatinine ratio *4.28(2.5)*Values are expressed as mean (SD) or median (IQR) as appropriate Table 1Baseline characteristics of the study cohort (N = 54)VariableValuesN (%) Demographic characteristics Median age of onset(years)5.0 (4.0, 9.0) Gender MaleFemale36 (66.7)18 (33.3) Status of nephrotic syndrome First episodeRelapse(FRNS, IFRNS, SDNS)44 (81.5)10 (18.5) Geographical Distribution Hilly regionTerai region7(13)47(87) Socio-economic status Upper middle classLower middle classUpper lower class17(31.5)29(53.7)8(14.8) Clinical Features at Presentation Edema FacialPedalGeneralized10(18.5)17(31.5)27(50)Anemia9 (16.7)Hematuria (Microscopic)3 (5.6)Hypertension5 (9.3)Acute Kidney Injury (AKI)4 (7.4)Hyponatremia18 (33.3)Hypokalemia2 (3.7) Laboratory Parameters Hemoglobin(g/dl) *12.3(1.4).Urea(mg/dl) *24.0 (17.7, 34.0)Creatinine(mg/dl) *0.4 (0.3, 0.5)Sodium(mEq/L) *136.5(133.7,138.2)Potassium(mEq/L) *4.3(3.9,4.7)Total protein(g/dl) *4.4 (0.4)Serum Albumin(g/dl) *1.8(0.4)Total Cholesterol(mg/dl) *430.5(125.8)Serum LDL (mg/dl) *295.4(95)Serum HDL (mg/dl) *71.9 (24.8)Serum VLDL (mg/dl) *49.5 (36.8, 62.6)Serum Triglycerides(mg/dl) *250.5(188.5,341)24 h urinary protein(mg/m2/hr) *74(51.5,87)Spot urine protein: creatinine ratio *4.28(2.5)*Values are expressed as mean (SD) or median (IQR) as appropriate Baseline characteristics of the study cohort (N = 54) Gender Male Female 36 (66.7) 18 (33.3) Status of nephrotic syndrome First episode Relapse (FRNS, IFRNS, SDNS) 44 (81.5) 10 (18.5) Geographical Distribution Hilly region Terai region 7(13) 47(87) Socio-economic status Upper middle class Lower middle class Upper lower class 17(31.5) 29(53.7) 8(14.8) Edema Facial Pedal Generalized 10(18.5) 17(31.5) 27(50) *Values are expressed as mean (SD) or median (IQR) as appropriate Time to remission and comparison of early and late responder groups The mean time to achieve remission was 8.6 ± 1.7 days. Based on a 9-day cut-off, 32 (59.2%) participants were classified as early responders and 22 (40.8%) as late responders. As shown in Table 2, no significant associations were found between demographic or clinical variables and time to remission. However, a trend towards delayed remission was observed in patients with hypertension at presentation (p = 0.061). Table 2Comparison between early and late respondersVariableEarly Responders n = 32(%)Late Respondersn = 22(%)p-value* Age of onset 0.845 ≤5 years21 (65.6)15 (68.2) >5 years11 (34.4)7 (31.8) Gender 0.845 Female11 (34.4)7 (31.8) Male21 (65.6)15 (68.2) Religion 0.375Hindu30(61.2)19(38.8)Muslim2(40)3(60) Geographical Distribution 0.903Hilly4(57.1)3(42.9)Terai28(59.5)19(40.5) Socio-economic status 0.317Upper middle class8(47)9(53)Lower middle class18(62.1)11(37.9)Upper lower class6(75)2(25) Episode type 0.501 First episode27 (84.4)17 (77.3) Relapse5 (15.6)5 (22.7) Hypertension* 0.06 Absent31 (96.9)18 (81.8) Present1 (3.1)4 (18.2) Hematuria* 0.155 Absent31 (96.9)20 (90.9) Present1 (3.1)2 (9.1) AKI 0.554 Absent29 (90.6)21 (95.5) Present3 (9.4)1 (4.5)#Chi-square test or Fisher’s exact test as appropriate, *-trend towards significance Table 2Comparison between early and late respondersVariableEarly Responders n = 32(%)Late Respondersn = 22(%)p-value* Age of onset 0.845 ≤5 years21 (65.6)15 (68.2) >5 years11 (34.4)7 (31.8) Gender 0.845 Female11 (34.4)7 (31.8) Male21 (65.6)15 (68.2) Religion 0.375Hindu30(61.2)19(38.8)Muslim2(40)3(60) Geographical Distribution 0.903Hilly4(57.1)3(42.9)Terai28(59.5)19(40.5) Socio-economic status 0.317Upper middle class8(47)9(53)Lower middle class18(62.1)11(37.9)Upper lower class6(75)2(25) Episode type 0.501 First episode27 (84.4)17 (77.3) Relapse5 (15.6)5 (22.7) Hypertension* 0.06 Absent31 (96.9)18 (81.8) Present1 (3.1)4 (18.2) Hematuria* 0.155 Absent31 (96.9)20 (90.9) Present1 (3.1)2 (9.1) AKI 0.554 Absent29 (90.6)21 (95.5) Present3 (9.4)1 (4.5)#Chi-square test or Fisher’s exact test as appropriate, *-trend towards significance Comparison between early and late responders #Chi-square test or Fisher’s exact test as appropriate, *-trend towards significance As shown in Table 3, there were no statistically significant differences in baseline laboratory variables between the early and late responder groups. Table 3Comparison of continuous laboratory variables between early and late respondersVariableEarly Responders (n = 32)Late Responders (n = 22)p-valueAge of onset (years)†5.5 (4.3, 9.0)5.0 (3.0, 9.0)0.522Hemoglobin (g/dL) ‡12.2(1.4)12.6(1.4)0.331Blood urea (mg/dL) †26.5(16.0,33.5)22.5 (19.0, 34.5)0.785Serum creatinine (mg/dL) †0.4 (0.3, 0.5)0.4 (0.3, 0.5)0.578Serum sodium (meq/L) †138(134,139)135(131.5,139)0.280Serum albumin (g/dL) ‡1.9(0.5)1.8(0.4)0.373Total cholesterol (mg/dL) ‡421.8(113.4)443.3(144.9)0.543Serum LDL (mg/dL) ‡287.9(95.8)306.3(94.9)0.491Serum HDL (mg/dL) ‡71.4(23.9)72.6(26.7)0.864Serum Triglycerides (mg/dL) †250(185.5,347)249(209,330)0.860Serum VLDL (mg/dL) †49.3(37.1,68.0)49.6 (32.6, 62.0)0.433† Mann-Whitney U test; data are expressed as median (IQR), ‡ Independent student’s t-test; data expressed as mean (SD) Table 3Comparison of continuous laboratory variables between early and late respondersVariableEarly Responders (n = 32)Late Responders (n = 22)p-valueAge of onset (years)†5.5 (4.3, 9.0)5.0 (3.0, 9.0)0.522Hemoglobin (g/dL) ‡12.2(1.4)12.6(1.4)0.331Blood urea (mg/dL) †26.5(16.0,33.5)22.5 (19.0, 34.5)0.785Serum creatinine (mg/dL) †0.4 (0.3, 0.5)0.4 (0.3, 0.5)0.578Serum sodium (meq/L) †138(134,139)135(131.5,139)0.280Serum albumin (g/dL) ‡1.9(0.5)1.8(0.4)0.373Total cholesterol (mg/dL) ‡421.8(113.4)443.3(144.9)0.543Serum LDL (mg/dL) ‡287.9(95.8)306.3(94.9)0.491Serum HDL (mg/dL) ‡71.4(23.9)72.6(26.7)0.864Serum Triglycerides (mg/dL) †250(185.5,347)249(209,330)0.860Serum VLDL (mg/dL) †49.3(37.1,68.0)49.6 (32.6, 62.0)0.433† Mann-Whitney U test; data are expressed as median (IQR), ‡ Independent student’s t-test; data expressed as mean (SD) Comparison of continuous laboratory variables between early and late responders † Mann-Whitney U test; data are expressed as median (IQR), ‡ Independent student’s t-test; data expressed as mean (SD) Binary logistic regression analysis was performed to determine predictors of early vs. late responders with time to remission as dependent variable and clinical variables like age of onset, gender, hypertension, hematuria, episode category, AKI and laboratory variables like hemoglobin, serum albumin, urea, creatinine, cholesterol, HDL, LDL, VLDL, triglycerides as independent variables. None of the variables were statistically significant in univariate or multivariate analyses with p-value > 0.05 as represented in Table 4. However, after adjusting age of onset, hypertension (Odd’s Ratio-0.42, confidence interval,0.65–2.81, p value-0.370) and hematuria (Odd’s Ratio-0.3, confidence interval,0.86–3.65, p value-0.351) remained associated with delayed remission. Similarly, baseline continuous laboratory variables between early(n = 32) and late responders(n = 22) revealed no significant differences in age of onset, serum albumin, hemoglobin, renal function and lipid profile (all p-values > 0.05). Table 4Logistic regression of predictors of late remission in children with SSNSVariableUnivariate analysisMultivariate analysisOdd’s ratio (95% CI)p-valueAdjusted Odd’s ratio (95% CI)p-valueAge of onset(years)1.12(0.35–3.56)0.8451.14(0.32–4.06)0.839Gender (male vs. female)1.10(0.34–3.56)0.8680.89(0.21–3.66)0.877Hypertension (yes vs. no)0.42(0.11–1.62)0.3700.35(0.11–1.55)0.314Hematuria (present vs. absent)0.30(0.86–3.65)0.3510.23(0.05–1.37)0.290AKI (yes vs. no)0.45(0.04–4.69)0.810--Hemoglobin (g/dl)1.21(0.82–1.81)0.3200.23(0.16–3.45)0.713Serum albumin(g/dl)0.57(0.17–1.90)0.3600.39(0.92–1.68)0.208Urea(mg/dl)0.99(0.96–1.03)0.890--Creatinine(mg/dl)1.00(0.13–7.43)0.990--Cholesterol(mg/dl)1.00(0.99-1.00)0.5301.00(0.99-1.00)0.837HDL (mg/dl)1.00(0.98–1.02)0.860--LDL (mg/dl)1.00(0.99-1.00)0.8601.00(0.99–1.01)0.908VLDL (mg/dl)0.99(0.97–1.01)0.3500.98(0.96-1.00)0.237Triglyceride (mg/dl)0.99(0.99-1.00)0.62--*Variables with p < 0.2 in univariate analysis and clinically relevant covariates were included in multivariate model, “–” indicates variable not included in multivariate model Table 4Logistic regression of predictors of late remission in children with SSNSVariableUnivariate analysisMultivariate analysisOdd’s ratio (95% CI)p-valueAdjusted Odd’s ratio (95% CI)p-valueAge of onset(years)1.12(0.35–3.56)0.8451.14(0.32–4.06)0.839Gender (male vs. female)1.10(0.34–3.56)0.8680.89(0.21–3.66)0.877Hypertension (yes vs. no)0.42(0.11–1.62)0.3700.35(0.11–1.55)0.314Hematuria (present vs. absent)0.30(0.86–3.65)0.3510.23(0.05–1.37)0.290AKI (yes vs. no)0.45(0.04–4.69)0.810--Hemoglobin (g/dl)1.21(0.82–1.81)0.3200.23(0.16–3.45)0.713Serum albumin(g/dl)0.57(0.17–1.90)0.3600.39(0.92–1.68)0.208Urea(mg/dl)0.99(0.96–1.03)0.890--Creatinine(mg/dl)1.00(0.13–7.43)0.990--Cholesterol(mg/dl)1.00(0.99-1.00)0.5301.00(0.99-1.00)0.837HDL (mg/dl)1.00(0.98–1.02)0.860--LDL (mg/dl)1.00(0.99-1.00)0.8601.00(0.99–1.01)0.908VLDL (mg/dl)0.99(0.97–1.01)0.3500.98(0.96-1.00)0.237Triglyceride (mg/dl)0.99(0.99-1.00)0.62--*Variables with p < 0.2 in univariate analysis and clinically relevant covariates were included in multivariate model, “–” indicates variable not included in multivariate model Logistic regression of predictors of late remission in children with SSNS *Variables with p < 0.2 in univariate analysis and clinically relevant covariates were included in multivariate model, “–” indicates variable not included in multivariate model Discussion In this prospective observational study of 54 children with SSNS, we sought to identify predictors of time to remission after initiation of steroid therapy. We observed a good compliance to steroid treatment; urine dipstick monitoring and follow up. Among the relapse cases, 6 cases (60%) presented with infection, however there were no complicated relapse as per ISPN guidelines. The median age of onset was 5.0 years (IQR: 4.0, 6.0) similar to the study done by Passini et al. [8]. Most of the cases(49, 90.7%) in our study belonged to Hindu community in contrast to the study done by Rai VK et al. [5] where Muslim community was predominant. Most cases of our study belonged to middle class (85.2%) similar to the study done by Aliyu et al. [9] which could be the true reflection of the social and economic background of people in developing countries like Nepal. The mean time to remission was 8.6 ± 1.7 days, and most patients (59.2%) were early responders, achieving remission within 9 days, consistent with findings from other studies [10]. Despite analyzing multiple demographic, clinical, and biochemical parameters, we did not find statistically significant predictors of time to remission similar to the study done by Nardini et al. [11]. These data support the conclusion that routine baseline parameters are of limited value in predicting time to remission in SSNS. A notable trend in our data was the potential association between late response to remission and the presence of hypertension (p = 0.061) or hematuria at presentation. Although hypertension and hematuria did not reach statistical significance, their consistent association with slower remission across several studies suggests they may reflect more severe underlying glomerular inflammation, a hypothesis that warrants further investigation. The logistic regression model also did not demonstrate any variable with independent predictive value. However, other studies have also reported a lack of significant association between these variables and remission time, suggesting their predictive value may be limited [12]. Our finding is similar to the study done by Carter et al. where they concluded demographic, clinical and family related characteristics are not useful in predicting remission and relapses [13]. The male-to-female ratio of 2:1 in our cohort is consistent with the well-documented male predominance in childhood nephrotic syndrome [14]. We found no difference in remission time between males and females, a finding also reported by Bhatta et al. [14]. Similarly, age at onset did not predict response time in our cohort, though some studies have suggested younger age may be associated with delayed remission [10]. Dyslipidemia is a hallmark of nephrotic syndrome. In our study, we observed a non-significant trend of higher mean cholesterol, VLDL, and LDL levels in late responders. This pattern has been noted by other investigators [5, 10], but like our study, they did not find a statistically significant link. This suggests that while lipid abnormalities are central to the pathophysiology, baseline lipid levels may not be sensitive enough to predict the speed of response to steroids. Our separate analysis of first episode versus relapse cases did not yield significant predictors, though it hinted at potential alterations in lipid metabolism in patients with multiple relapses, warranting further investigation. This is the first study from Nepal on predictors of remission in SSNS which provides novel data on steroid response in Nepalese children with comprehensive inclusion of variables giving holistic assessment. However, this study has several limitations. First, the single-center design and relatively small sample size (N = 54) limited the statistical power to detect modest associations and may explain the lack of significant findings. The trend observed with hypertension, for instance, might have reached significance in a larger cohort. Second, the cut-off for defining early and late responders was determined post-hoc based on our data, which might affect reproducibility. Third, while we followed a standardized treatment protocol, we could not exclude the possibility that variations in prior management for relapse cases could have introduced bias. Fourth, unavailability of data on some potential confounders like treatment delays, prior infection status and nutritional status which could influence the outcome. Finally, a lack of comprehensive data from previous studies in this specific area made direct comparisons challenging. Conclusion In this cohort of Nepalese children with SSNS, no significant clinical, demographic, or laboratory predictors of time to remission following steroid therapy were found. While trends suggested that hypertension and hematuria might delay remission, these were not statistically significant. The findings underscore the complex and multifactorial nature of steroid response in nephrotic syndrome highlighting that common baseline parameters have limited predictive value for individual patients and may not guide prognosis in clinical practice. Large-scale, prospective, multi-center studies integrating biologic markers, genetic and immunologic profiling are needed to identify more reliable predictors and explore the potential role of novel biomarkers.